EHA 2025: Durable Undetectable MRD Responses with Acalabrutinib in CLL

Professor Paolo Ghia from Università Vita-Salute San Raffaele in Milan highlights new results from the AMPLIFI study presented at EHA 2025. The study shows that acalabrutinib combined with venetoclax, with or without obinutuzumab, achieves high rates of undetectable minimal residual disease (MRD) in healthy CLL patients. Crucially, patients who maintain undetectable MRD over time show promising long-term disease control and potentially a longer-term lower risk of disease progression or death compared to traditional immunochemotherapy.